Biotechnology Focus Podcast

On this weeks show, Accelerating precision medicine for cancer patients, Avivagen partners with NRC to tackle antibiotic resistance in humans, and Knight buys in on an Israeli biotech, We have all this and more on this week’s Biotechnology Focus Radio Show Podcast. Welcome to another episode of Biotechnology Focus Podcast. I’m your host Shawn Lawrence, here to give you a rundown of this week’s top stories on the Canadian biotech scene, Story Montreal’s Knight Therapeutics-a specialty pharma company reports it is taking a small stake in an Israeli-based company, Protalix BioTherapeutics, through the acquisition of 6,200,000 common shares of the company at an average price of US$0.57 per share. With the purchase, Knight now owns approximately five per cent of the outstanding common shares of Protalix. The shares were purchased by Abir Therapeutics Ltd., Knight’s wholly-owned Israeli headquartered subsidiary, which owns 28.3 per cent of Medison Pharma (Medison), Israel’s third largest pharmaceutical company rank